Nicotine Addiction Treatment Summary
DOI:
https://doi.org/10.12775/JEHS.2025.81.59950Keywords
nicotine addiction, smoking cessation, nrt, behavioral therapy, cytisine, varenicline, bupropion, pharmacotherapy, PolandAbstract
Nicotine addiction is a leading cause of preventable illness and death worldwide. This review summarizes current treatment options, focusing on both behavioral and pharmacological methods used in Poland and internationally. Effective strategies include nicotine replacement therapy (NRT), medications like cytisine, varenicline, and bupropion, as well as structured psychotherapy. Combining medical and psychological approaches significantly improves cessation outcomes and reduces the global burden of tobacco use.
Introduction
Tobacco use remains a major global health issue, contributing to millions of deaths annually. Nicotine’s addictive properties make quitting challenging despite widespread awareness of its risks. Effective treatment requires a comprehensive approach, combining behavioral support and pharmacotherapy. This paper reviews current methods of nicotine addiction treatment, with an emphasis on practices in Poland and globally.
Aim of the Study
This study aims to present a clear overview of evidence-based nicotine addiction treatments, with a focus on therapies available in Poland. It evaluates the effectiveness of both behavioral and pharmacological interventions to support healthcare professionals in smoking cessation efforts.
Materials and Methods
A literature review was conducted using PubMed and Google Scholar. The study includes international and Polish guidelines, scientific articles, and clinical data related to nicotine addiction therapy. Sources span behavioral interventions, NRT, and pharmacological treatments like cytisine, varenicline, and bupropion.
Conclusion
Nicotine dependence is treatable through a combination of behavioral and pharmacological methods. In Poland, comprehensive treatment programs and modern pharmacotherapy are available and effective. Increasing access to these resources is essential to reducing smoking rates and improving public health.
References
1. Global Burden of Disease. (2019). Institute of Health Metrics [Database]. Washington, DC: IHME. Retrieved July 17, 2023.
2. Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004). Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ, 328(7455), 1519.
3. Siddiqi, K., Husain, S., Vidyasagaran, A., et al. (2020). Global burden of disease due to smokeless tobacco consumption in adults: An updated analysis of data from 127 countries. BMC Medicine, 18, 222.
4. World Health Organization. (2022). Tobacco: Key facts. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/tobacco (Accessed June 15, 2023).
5. NF Health. (2021). Tobacco-related diseases: Report 2021. National Health Fund.
6. Polish Lipidological Society. (2022). Guidelines for the treatment of nicotine addiction. In cooperation with and supported by WHO Poland. https://ptlipid.pl/wp-content/uploads/2022/05/art_1653901298_wytyczne-zun.pdf
7. Zatoński, W. (2005). How to quit smoking. Warsaw: PZWL.
8. Teesson, M., & Degenhardt, L. (2005). Addictions: Clinical models and therapeutic techniques for therapists. Gdańsk: Gdańsk Psychological Publishing.
9. Regulation of the Minister of Health. (2022, March 30). Amending the regulation on specialization in fields applicable to healthcare. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20220000744
10. Meng, Y., Xiang, S., Qu, L., & Li, Y. (2024). The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: A systemic review and network meta-analysis. Frontiers in Public Health, 12, 1361186. https://doi.org/10.3389/fpubh.2024.1361186
11. Sandhu, A., Hosseini, S. A., & Saadabadi, A. (2023). Nicotine replacement therapy. In StatPearls. Treasure Island (FL): StatPearls Publishing.
12. Hersi, M., Beck, A., Hamel, C., et al. (2024). Effectiveness of smoking cessation interventions among adults: An overview of systematic reviews. Systematic Reviews, 13(1), 179. https://doi.org/10.1186/s13643-024-02570-9
13. Lindson-Hawley, N., Hartmann-Boyce, J., Fanshawe, T. R., et al. (2016). Interventions to reduce harm from continued tobacco use. Cochrane Database of Systematic Reviews, 10, CD005231. https://doi.org/10.1002/14651858.CD005231.pub3
14. Wallström, M., Sand, L., Nilsson, F., & Hirsch, J. M. (1999). The long-term effect of nicotine on the oral mucosa. Addiction, 94(3), 417–423. https://doi.org/10.1046/j.1360-0443.1999.94341711.x
15. Myers Smith, K., Phillips-Waller, A., Pesola, F., et al. (2022). E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: Randomized controlled trial. Addiction, 117(1), 224–233. https://doi.org/10.1111/add.15628
16. Hajek, P., Phillips-Waller, A., Przulj, D., et al. (2019). A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine, 380(7), 629–637. https://doi.org/10.1056/NEJMoa1808779
17. Theodoulou, A., Chepkin, S. C., Ye, W., et al. (2023). Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 6, CD013308. https://doi.org/10.1002/14651858.CD013308.pub2
18. Shete, A., Shete, M., & Lolage, V. (2024). Nicotine replacement therapy: A clinical approach. New Visions in Medicine and Medical Science, 6. https://doi.org/10.9734/bpi/nvmms/v6/8426E
19. Hartmann-Boyce, J., Lindson, N., Butler, A. R., et al. (2022). Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews, 11, CD010216. https://doi.org/10.1002/14651858.CD010216.pub7
20. Glasser, A. M., Collins, L., Pearson, J. L., et al. (2017). Overview of electronic nicotine delivery systems: A systematic review. American Journal of Preventive Medicine, 52(2), e33–e66. https://doi.org/10.1016/j.amepre.2016.10.036
21. Stead, L. F., Perera, R., Bullen, C., et al. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 11, CD000146. https://doi.org/10.1002/14651858.CD000146.pub4
22. World Health Organization. (2023). WHO report on the global tobacco epidemic 2023: Monitoring tobacco use and prevention policies. Geneva: WHO. https://www.who.int/publications/i/item/9789240068766
23. Łuszczki, J. J., & Misiuta-Krzesińska, M. (2017). Assessment and mechanisms of cognitive effects of alkaloid compounds. In M. Król, M. Kieć-Kononowicz, & M. Sienkiewicz-Jarosz (Eds.), Neurobiology: Short Lectures (pp. 485–504). Warsaw: PWN Scientific Publishing.
24. Kozłowski, D., & Kaczmarek, L. (2018). Cytisine in the treatment of smoking cessation. Medical Reader.
25. Brennan, P. K., & Lanza, S. T. (2016). Varenicline – A safe and effective drug for supporting smoking cessation. TerMedia.
26. European Medicines Agency. (2011). Champix, INN-varenicline.
27. Wilkes, S. (2008). The use of bupropion SR in cigarette smoking cessation. International Journal of Chronic Obstructive Pulmonary Disease, 3(1), 45–53. https://doi.org/10.2147/copd.s1121
28. Martinez-Raga, J., Keaney, F., Sutherland, G., et al. (2003). Treatment of nicotine dependence with bupropion SR: Review of its efficacy, safety and pharmacological profile. Addiction Biology, 8(1), 13–21. https://doi.org/10.1080/1355621031000069837
29. Mooney, M. E., & Sofuoglu, M. (2006). Bupropion for the treatment of nicotine withdrawal and craving. Expert Review of Neurotherapeutics, 6(7), 965–981. https://doi.org/10.1586/14737175.6.7.965
30. Gourlay, S. G., Stead, L. F., & Benowitz, N. (2004). Clonidine for smoking cessation. Cochrane Database of Systematic Reviews, 3, CD000058. https://doi.org/10.1002/14651858.CD000058.pub2
31. Sees, K. L., & Stalcup, S. A. (1989). Combining clonidine and nicotine replacement for treatment of nicotine withdrawal. Journal of Psychoactive Drugs, 21(3), 355–359. https://doi.org/10.1080/02791072.1989.10472177
32. Glassman, A. H., Covey, L. S., Dalack, G. W., et al. (1993). Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clinical Pharmacology & Therapeutics, 54(6), 670–679. https://doi.org/10.1038/clpt.1993.205
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Michał Hofman, Julia Janecka, Filip Nadolny, Alicja Śniatała, Jędrzej Jabłoński, Adam Dudek, Martyna Kania, Agnieszka Adamowska, Hanna Bartkowiak, Damian Grubski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 186
Number of citations: 0
